Infinity Pharmaceuticals, Inc. engages in the discovery and development of medicines for the treatment of cancer and related conditions in the United States. Its lead product candidate includes IPI-504 (retaspimycin hydrochloride), an intravenously-administered small molecule inhibitor of heat shock protein 90 (Hsp90). The company is conducting an international Phase II clinical trial of IPI-504 in combination with Herceptin in patients with HER2-positive metastatic breast cancer; a Phase II clinical trial of IPI-504 in patients with advanced non-small cell lung cancer; and a Phase I clinical trial of IPI-504 in combination with Taxotere in patients with advanced solid tumors. Its products under Phase I clinical trial comprise IPI-493, an orally-delivered inhibitor of Hsp90, in patients with advanced solid tumors; IPI-926 for patients with advanced and/or metastatic solid tumors; and IPI-940, an orally-delivered inhibitor of fatty acid amide hydrolase for the treatment of neuropathic and inflammatory pain. Infinity Pharmaceuticals has strategic alliance agreements with Purdue Pharmaceutical Products L.P. and Mundipharma International Corporation Limited; an agreement with MedImmune, Inc. to develop and commercialize cancer drugs targeting Hsp90 and the hedgehog pathway; and a collaboration agreement with Novartis Institute for BioMedical Research, Inc. to discover, develop, and commercialize drugs targeting Bcl protein family members for the treatment of cancers. The company is headquartered in Cambridge, Massachusetts.

Patents 526show all

  • 138
    C07D - Heterocyclic compounds
  • 131
    A61K - Preparations for medical, dental, or toilet purposes
  • 49
    C07F - Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
  • 29
    Y02A - Technologies for adaptation to climate change
  • 25
    C07B - General methods of organic chemistry
  • 15
    G01N - Investigating or analysing materials by determining their chemical or physical properties
  • 11
    C07J - Steroids
  • 6
    C12Q - Measuring or testing processes involving enzymes, nucleic acids or microorganisms
  • 5
    C07K - Peptides
  • 4
    B01J - Chemical or physical processes, e.g. catalysis or colloid chemistry

Clinical Trials 90show all

32N/A23Phase 220Phase 312Phase 13Other

SEC Filings show all


221
8-K

59
10-Q

19
10-K

2
D

1
S-1

Contact Information

780 Memorial Drive
Cambridge, MA 02139
United States

Overview

Total FundingEmployeesLast Funding DateStatus
$276,040,19151-1002020-01-09Ipo

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2020-01-09$20,000,000Post Ipo EquityBVF Partners
2002-01-01Series UnknownAdvent Life Sciences
2012-09-07$78,540,191Post Ipo Equity
2004-01-08$25,000,000Series UnknownAmgen Ventures
2008-11-20$75,000,000Series UnknownPurdue Pharma
2012-07-19$27,500,000Post Ipo EquityPurdue Pharma
2011-11-29$50,000,000Post Ipo DebtMundipharma

SEC Form D Funding Events

DateOfferedSoldType
2012-09-24$78,540,191$78,540,191Equity
2008-12-08Unknown Unknown Other (Paper Filing)

Key Executives

  • Adelene Q. Perkins
    Executive Officer, Director
  • Julian Adams
    Executive Officer
  • Vito J. Palombella
    Executive Officer
  • Pedro Santabarbara
    Executive Officer
  • Steve H Holtzman
    Director
  • Martin Babler
    Director
  • Anthony B. Evnin
    Director
  • Gwen A. Fyfe
    Director
  • Eric S. Lander
    Director
  • Patrick P Lee
    Director
  • Thomas J. Lynch
    Director
  • Norman C. Selby
    Director
  • Ian F. Smith
    Director
  • Michael C. Venuti
    Director